蒂尔泽帕提德用于治疗脂质疏松症
medRxiv : the preprint server for health sciences
|January 13, 2025
概括
蒂尔泽帕提德在治疗罕见的代谢障碍脂质变症方面表现有前途. 这种双重的隐素药物显著改善了部分或泛性脂质变质症患者的BMI,HbA1c和甘油三水平.
科学领域:
- 内分泌学和新陈代谢学
- 罕见的遗传疾病 罕见的遗传疾病
- 药理干预药理干预
背景情况:
- 脂质疏松症是一组罕见的疾病,其特点是脂肪分布异常和严重的代谢并发症.
- 在脂质缩中脂肪细胞质量减少导致异胎脂存储和代谢功能障碍.
- 之前的研究表明,在家族局部脂质缩症 (FPLD) 中,类似葡萄糖素的-1激动剂有好处.
研究的目的:
- 为了研究双重基素的提尔泽帕提德的疗效,作为诊断为脂质营养不良的患者的潜在治疗方法.
- 评估蒂尔泽帕提德对部分脂质变 (PL) 或泛性脂质变 (GL) 个体的代谢参数的影响.
主要方法:
- 一项观察性队列研究跟踪了PL或GL患者,这些患者在临床上接受了提尔泽帕提德治疗.
- 数据是在正在进行的脂质营养不良的自然历史研究的框架内收集的.
- 17名患者 (14名患有FPLD,3名患有获得的GL) 接受了蒂尔泽帕提德,随着时间的推移对代谢标志物进行了监测.
主要成果:
- 在FPLD患者中,提尔泽帕提德治疗导致BMI,HbA1c,甘油三水平和每日胰岛素需求显著降低.
- 获得性泛性脂质变 (GL) 患者的BMI,HbA1c,甘油三和胰岛素需求也显著改善.
- 三名患者经历了剂量限制的胃食道逆流,阻碍了进一步的剂量升级.
结论:
- 提尔泽帕提德显示出作为有效治疗剂的潜力,用于管理脂质营养不良患者的代谢障碍.
- 这些发现支持进一步调查提尔泽帕提德用于治疗脂质疏松症,尽管存在一些耐受性问题.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Cholesterol: Significance and Regulation
499
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
499
Overview of Lipid Metabolism
997
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
997
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
526
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
526
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141


